Sign up to save your podcasts
Or
Share Novel Clinical Approaches in Multiple Myeloma: CAR T Cell Therapy
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Novel Clinical Approaches in Multiple Myeloma: CAR T Cell Therapy
CME credits: 0.25
Valid until: 22-04-2023
Claim your CME credit at https://reachmd.com/programs/cme/novel-clinical-approaches-in-multiple-myeloma-car-t-cell-therapy/13429/
Two newly approved BCMA-directed CAR T cell therapies, idecabtagene vicleucel and ciltacabtagene autoleucel, are providing patients with the prospect of deep and durable remissions. Maximizing the potential of CAR T cell therapy can provide improved length and quality of life for patients with multiply relapsed multiple myeloma. Join us as Dr. Sagar Lonial and Dr. Noopur Raje discuss the available treatment options, current applications of the clinical data, and strategies to improve care for your patients with multiple myeloma who may be candidates for CAR T cell therapy.
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.25
Valid until: 22-04-2023
Claim your CME credit at https://reachmd.com/programs/cme/novel-clinical-approaches-in-multiple-myeloma-car-t-cell-therapy/13429/
Two newly approved BCMA-directed CAR T cell therapies, idecabtagene vicleucel and ciltacabtagene autoleucel, are providing patients with the prospect of deep and durable remissions. Maximizing the potential of CAR T cell therapy can provide improved length and quality of life for patients with multiply relapsed multiple myeloma. Join us as Dr. Sagar Lonial and Dr. Noopur Raje discuss the available treatment options, current applications of the clinical data, and strategies to improve care for your patients with multiple myeloma who may be candidates for CAR T cell therapy.
=